Inventor
David BELLOVIN
Inventor
US
Overview
Patents· 8 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes29%
C07KPeptides29%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%
C12NMicroorganisms or enzymes7%
G01NInvestigating or analysing materials by determining their chemical or physical properties7%
C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4%
PatentTitleYear
12,565,527IL13 and IL31 bispecific polypeptides and uses thereof202612,509,510IL31-binding polypeptides and uses thereof202512,365,719CD80 extracellular domain polypeptides and their use in cancer treatment202511,814,431B7-H4 antibodies and methods of use thereof202311,566,076Anti-CSF1R antibody and anti-PD-1 antibody combination therapy for selected cancers202311,559,583Anti-CSF1R antibody and agonistic anti-CD40 antibody combination therapy for cancer202311,421,034Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer202211,306,144B7-H4 antibodies and methods of use thereof2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2025Patents assigned to FIVE PRIME THERAPEUTICS INC (6)· patent assignee history
2022–2023Patents assigned to BRISTOL MYERS SQUIBB CO (2)· patent assignee history
2022–2026Based in US· patent location history
2025–2026Patents assigned to ATTOVIA THERAPEUTICS INC (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| FIVE PRIME THERAPEUTICS INC | 6 | 2022–2025 |
| ATTOVIA THERAPEUTICS INC | 2 | 2025–2026 |
| BRISTOL MYERS SQUIBB CO | 2 | 2022–2023 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 8 | 2022–2026 |